Physician profile
Daniel T Kulick
NPI 1720206600
$2,238.35
in general payments reported to CMS, 2019-2025
21 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.01 · 2020: $184 · 2021: $461 · 2022: $490 · 2023: $467 · 2024: $320 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $421.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $409.65 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $191.40 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $185.21 | 2020-2021 | |
| Lilly USA, LLC | $159.69 | 2022-2025 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $126.09 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $97.87 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Exact Sciences Corporation | $94.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $87.82 | 2021-2023 | Yupelri |
| Axsome Therapeutics, INC. | $69.25 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $61.58 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.46 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.09 | 2022-2023 | Trintellix |
| Boston Scientific Corporation | $42.34 | 2024 | Rotapro |
| Glaxosmithkline, LLC. | $39.69 | 2020-2024 | Trelegy Ellipta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.57 | 2023 | |
| Optinose US, INC. | $29.60 | 2024 | |
| Allergan, INC. | $26.58 | 2020 | |
| Supernus Pharmaceuticals, INC. | $24.63 | 2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.13 | 2024 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $16.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kulick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.